Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Amarin Files Over Icosapent Ethyl Capsules And Cardiovascular Indication Patents
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
You may also be interested in...
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.